Any feedback?
Literature summary extracted from
- Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use (2008), Chem. Biol. Drug Des., 71, 298-305.
Cloned(Commentary)
| EC Number | Cloned (Comment) | Organism |
|---|---|---|
| 3.4.23.47 | expressed in Escherichia coli | Human immunodeficiency virus 2 |
Inhibitors
| EC Number | Inhibitors | Comment | Organism | Structure |
|---|---|---|---|---|
| 3.4.23.47 | amprenavir | - |
Human immunodeficiency virus 2 |  |
| 3.4.23.47 | atazanavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | darunavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | indinavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | KNI-764 | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | lopinavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | nelfinavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | ritonavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | saquinavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | tipranavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | TMC-126 | - |
Human immunodeficiency virus 2 | |
KM Value [mM]
| EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
|---|---|---|---|---|---|---|
| 3.4.23.47 | 0.05 | - |
Lys-Ala-Arg-Val-Nle-p-nitrophenylalanine-Glu-Ala-Nle-NH2 | - |
Human immunodeficiency virus 2 | |
Organism
| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 3.4.23.47 | Human immunodeficiency virus 2 | - |
- |
- |
Purification (Commentary)
| EC Number | Purification (Comment) | Organism |
|---|---|---|
| 3.4.23.47 | using anion-exchange Q-Sepharose column | Human immunodeficiency virus 2 |
Storage Stability
| EC Number | Storage Stability | Organism |
|---|---|---|
| 3.4.23.47 | stored at -20°C without loss of activity | Human immunodeficiency virus 2 |
Substrates and Products (Substrate)
| EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|---|
| 3.4.23.47 | Lys-Ala-Arg-Val-Nle-p-nitrophenylalanine-Glu-Ala-Nle-NH2 + H2O | - |
Human immunodeficiency virus 2 | ? | - |
? | |
Synonyms
| EC Number | Synonyms | Comment | Organism |
|---|---|---|---|
| 3.4.23.47 | HIV-2 protease | - |
Human immunodeficiency virus 2 |
Temperature Optimum [°C]
| EC Number | Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
|---|---|---|---|---|
| 3.4.23.47 | 25 | - |
assay at | Human immunodeficiency virus 2 |
Turnover Number [1/s]
| EC Number | Turnover Number Minimum [1/s] | Turnover Number Maximum [1/s] | Substrate | Comment | Organism | Structure |
|---|---|---|---|---|---|---|
| 3.4.23.47 | 5.3 | - |
Lys-Ala-Arg-Val-Nle-p-nitrophenylalanine-Glu-Ala-Nle-NH2 | - |
Human immunodeficiency virus 2 | |
pH Optimum
| EC Number | pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
|---|---|---|---|---|
| 3.4.23.47 | 5 | - |
assay at | Human immunodeficiency virus 2 |
Ki Value [mM]
| EC Number | Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
|---|---|---|---|---|---|---|
| 3.4.23.47 | 0.00000016 | - |
TMC-126 | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | 0.00000017 | - |
darunavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | 0.00000045 | - |
tipranavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | 0.0000006 | - |
saquinavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | 0.0000007 | - |
lopinavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | 0.0000008 | - |
ritonavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | 0.0000013 | - |
indinavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | 0.0000014 | - |
KNI-764 | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | 0.0000024 | - |
atazanavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | 0.0000027 | - |
nelfinavir | - |
Human immunodeficiency virus 2 | |
| 3.4.23.47 | 0.0000044 | - |
amprenavir | - |
Human immunodeficiency virus 2 | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
